Full title: A randomised phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer The Synergism Or Long Duration (SOLD) study Cancer type: Breast Status: In Follow-Up Brief description:   This trial involves early breast … Continue reading SOLD